Another perspective on MAC prophylaxis. Interview by Gordon Nary.
Pierce
M
M
Vanderbilt University, Medical Center, AIDS Clinical Trials Unit, Nashville, TN.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D017291:Clarithromycin / Q000627:therapeutic use; D017277:Drug Approval; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000150:complications / Q000517:prevention & control*; D017828:Rifabutin / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000995:Antitubercular Agents; D017828:Rifabutin; D017291:Clarithromycin